Zaki MH - Search Results

1

The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1.

Cavarretta IT, Neuwirt H, Untergasser G, Moser PL, Zaki MH, Steiner H, Rumpold H, Fuchs D, Hobisch A, Nemeth JA, Culig Z. Cavarretta IT, et al. Among authors: zaki mh. Oncogene. 2007 May 3;26(20):2822-32. doi: 10.1038/sj.onc.1210097. Epub 2006 Oct 30. Oncogene. 2007. PMID: 17072336

2

Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328.

Steiner H, Cavarretta IT, Moser PL, Berger AP, Bektic J, Dietrich H, Zaki MH, Nakada M, Hobisch A, Nemeth JA, Culig Z. Steiner H, et al. Among authors: zaki mh. Prostate. 2006 Dec 1;66(16):1744-52. doi: 10.1002/pros.20492. Prostate. 2006. PMID: 16998813

3

Mcl-1 is regulated by IL-6 and mediates the survival activity of the cytokine in a model of late stage prostate carcinoma.

Cavarretta IT, Neuwirt H, Zaki MH, Steiner H, Hobisch A, Nemeth JA, Culig Z. Cavarretta IT, et al. Among authors: zaki mh. Adv Exp Med Biol. 2008;617:547-55. doi: 10.1007/978-0-387-69080-3_56. Adv Exp Med Biol. 2008. PMID: 18497081

4

Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice.

Wallner L, Dai J, Escara-Wilke J, Zhang J, Yao Z, Lu Y, Trikha M, Nemeth JA, Zaki MH, Keller ET. Wallner L, et al. Among authors: zaki mh. Cancer Res. 2006 Mar 15;66(6):3087-95. doi: 10.1158/0008-5472.CAN-05-3447. Cancer Res. 2006. PMID: 16540658

5

CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice.

Zaki MH, Nemeth JA, Trikha M. Zaki MH, et al. Int J Cancer. 2004 Sep 10;111(4):592-5. doi: 10.1002/ijc.20270. Int J Cancer. 2004. PMID: 15239138

6

Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.

Voorhees PM, Chen Q, Kuhn DJ, Small GW, Hunsucker SA, Strader JS, Corringham RE, Zaki MH, Nemeth JA, Orlowski RZ. Voorhees PM, et al. Among authors: zaki mh. Clin Cancer Res. 2007 Nov 1;13(21):6469-78. doi: 10.1158/1078-0432.CCR-07-1293. Clin Cancer Res. 2007. PMID: 17975159

7

New biologic agents for the treatment of cutaneous T-cell lymphoma.

Vittorio CC, Junkins-Hopkins JM, McGinnis KS, Shapiro M, Wysocka M, Zaki MH, French LE, Rook AH. Vittorio CC, et al. Among authors: zaki mh. Recent Results Cancer Res. 2002;160:321-8. doi: 10.1007/978-3-642-59410-6_37. Recent Results Cancer Res. 2002. PMID: 12079230 Review.

8

Cutaneous castleman's disease responds to anti interleukin-6 treatment.

Ahmed B, Tschen JA, Cohen PR, Zaki MH, Rady PL, Tyring SK, Corringham RE, Kurzrock R. Ahmed B, et al. Among authors: zaki mh. Mol Cancer Ther. 2007 Sep;6(9):2386-90. doi: 10.1158/1535-7163.MCT-07-0256. Epub 2007 Aug 31. Mol Cancer Ther. 2007. PMID: 17766835

9

Chlamydia pneumoniae inhibits apoptosis in human peripheral blood mononuclear cells through induction of IL-10.

Geng Y, Shane RB, Berencsi K, Gonczol E, Zaki MH, Margolis DJ, Trinchieri G, Rook AH. Geng Y, et al. Among authors: zaki mh. J Immunol. 2000 May 15;164(10):5522-9. doi: 10.4049/jimmunol.164.10.5522. J Immunol. 2000. PMID: 10799921

10

Synergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2: basis for therapy of cutaneous T cell lymphoma.

Zaki MH, Wysocka M, Everetts SE, Wang KS, French LE, Ritz J, Rook AH. Zaki MH, et al. J Invest Dermatol. 2002 Feb;118(2):366-71. doi: 10.1046/j.1523-1747.2002.01646.x. J Invest Dermatol. 2002. PMID: 11841558 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

81 results

Search Page

Filters